Why the Clinuvel Pharmaceuticals share price is up 111% in 2018

The Clinuvel Pharmaceuticals Limited (ASX:CUV) share price has been a huge mover in 2018. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the local market this year has been the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price.

Since the start of the year the biopharmaceutical company's shares have risen a staggering 111%.

And that is despite its shares pulling back by over 30% since peaking at $24.10 in September.

Why has the Clinuvel Pharmaceuticals share price doubled in value this year?

For those that are not familiar with the company, Clinuvel is a global biopharmaceutical company which is focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.

Investors have been buying the company's shares this year due largely to the potential of its SCENESSE product.

SCENESSE has been developed as a first-line pharmaceutical product aimed at treating patients with the rare genetic disorder erythropoietic protoporphyria (EPP).

What is EPP?

The company explains that "EPP is a rare life-long genetic disease found mainly in fair-skinned people. It is characterised by severe phototoxicity (intolerance of light) of the skin resulting in intolerable pain, swelling and scarring, usually of exposed areas such as the face, hands and feet. Reactions can vary from mild to extreme with hospitalisation and powerful pain killers required in the worst cases."

Although the company estimates that just 4,000 people are affected by EPP in the U.S. and 10,000 globally, the product has the potential to generate meaningful revenues.

In fact, the product is available for sale in Europe at present and underpinned the company's latest jump in quarterly cash receipts.

Cash receipts rose 89% to $10.75 million in the September quarter.

And with its FDA filing now complete, it may not be long until the product is made available to U.S. sufferers. This would potentially give its cash receipts another sizeable boost.

Should you invest?

I like Clinuvel Pharmaceuticals and think it could be a good long term investment, however it is a reasonably high risk one.

So if you have a lower tolerance for risk you might be better off looking at the likes of CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX) instead.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Miner looking at his notes.
Industrials Shares

Forget BHP, this little known gem is roaring 30% in FY 2026

This little-known services company is quietly capitalising on mining and infrastructure activity across nine countries, and investors are starting to…

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a timid session for investors this Thursday.

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces.
ETFs

ASX ETFs: What do Bitcoin and video games have in common?

These funds are both up almost 100% in a year.

Read more »

Lion holding and screaming into a yellow loudspeaker on a blue background, symbolising an announcement from Liontown.
Share Gainers

Why EOS, Eroad, Neuren, and Westgold shares are roaring higher today

These shares are having a strong session on Thursday. But why?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

Today's session was one for the record books.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Infomedia, News Corp, REA Group, and West African shares are storming higher

These shares are having a great session on hump day. But why?

Read more »

A silhouette of a soldier flying a drone at sunset.
Share Gainers

Invested $10,000 in DroneShield shares in January? Guess how much that's worth today!

After being labelled overvalued in mid-2024, DroneShield shares have shot the lights out in 2025.

Read more »

Girl with painted hands.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a spectacular day for investors this Tuesday.

Read more »